Budesonide 'beneficial' for risky patients with mild COVID-19

Press/Media: Expert Comment

Description

Inhaled budesonide remains a useful option for treating symptoms of mild COVID-19 despite the advent of new oral antivirals, the RACGP’s quality care spokesman says.

Subject

Budesonide

COVID-19

General Practice

Period16 Feb 2022

Media contributions

1

Media contributions

  • TitleBudesonide 'beneficial' for risky patients with mild COVID-1
    Degree of recognitionNational
    Media name/outletAustralian Doctor
    Media typeWeb
    Country/TerritoryAustralia
    Date16/02/22
    DescriptionInhaled budesonide remains a useful option for treating symptoms of mild COVID-19 despite the advent of new oral antivirals, the RACGP’s quality care spokesman says.
    Producer/AuthorAntony Scholefield
    PersonsMark Morgan